Tharimmune, Inc. (Nasdaq: THAR) is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets. For more information please visit: www.tharimmune.com
Company Details
- Employees
- 5
- Address
- 1200 Route 22,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.tharimmune.com
- HQ
- Bridgewater, NJ
Tharimmune, Inc. Questions
Tharimmune, Inc.'s website is http://www.tharimmune.com
Tharimmune, Inc.'s LinkedIn profile is https://www.linkedin.com/company/tharimmune-inc
Tharimmune, Inc. has
5 employees.
View email and phone details for 5
employees at Tharimmune, Inc..
Tharimmune, Inc.'s industry is
Biotechnology Research
Tharimmune, Inc.'s top competitors are
Legend Biotech,
Kayothera,
Linusbio,
Tomi Environmental Solutions, Inc.,
Tharimmue,
Avior Bio Inc.,
Skunkworx Bio,
Citius Pharmaceuticals, Inc.,
Evrys Bio,
Cxo Executive Solutions, Llc.
Tharimmune, Inc.'s categories are Biotechnology Research
